RMMS Receives Continued Recognition in IAM Patent 1000 – Seven Firm Partners Individually Recognized

June 5, 2024 | Awards & Recognition

RMMS is once again honored to have been recognized as a leading intellectual property firm in the 2024 edition of IAM Patent 1000: The World’s Leading Patent Professionals, a guide to the top intellectual property law practitioners around the globe. The firm retained its strong ranking in the ‘Silver’ band for Intellectual Property Litigation.  

Regarding the firm’s work, IAM notes:

Premier boutique Rakoczy Molino Mazzochi Siwik stands as a top authority in life sciences patent litigation nationwide. The ensemble is well equipped to advocate for the leading producers of high-quality generic pharmaceuticals. The group’s track record speaks volumes: it has handled more than 300 Hatch-Waxman-related matters and boasts an impressive history of victories in final case resolutions.

RMMS is also pleased that many of our partners were recognized for their individual accomplishments. William Rakoczy again received a Gold ranking, with IAM recognizing that

“Rakoczy is widely recognized as one of the leading trial and appellate attorneys to the US pharmaceutical industry, leveraging his wealth of experience to secure victories.”

Paul Molino received a Silver ranking, with IAM noting “Molino emerges as an esteemed litigator, respected for his technical proficiency and expert navigation of patent disputes in the pharmaceutical and chemical sectors.”

Deanne Mazzochi, Kevin Warner, and Eric Hunt were newly recognized with a Bronze ranking while Rachel Pernic Waldron was again recognized by IAM, maintaining her Bronze ranking.  IAM notes that Ms. Mazzochi “brings a global perspective and is renowned for her expertise in Hatch-Waxman patent litigation; she is a go-to advocate for pharmaceutical clients,” while Mr. Warner “has honed his expertise in trial advocacy and counseling over nearly two decades.”  Ms. Waldron maintains “a dedicated focus on complex pharmaceutical litigations, notably within the realm of Hatch-Waxman disputes. She has earned acclaim for her representation of Sandoz in a pivotal case, securing a district court judgment invalidating the patent in question.”  Mr. Hunt “seamlessly blends his courtroom mastery with regulatory finesse, offering clients a comprehensive approach. Notably, he has spearheaded the growth of the biosimilar and biotechnology practice, guiding start-ups and leading institutional patrons through complex patent disputes, with agility.”

Additionally, Lara FitzSimmons was recognized as a recommended practitioner for transactional work, noting she “stands as a trusted adviser, with a keen eye for the intersection of legal and business imperatives. She smoothly guides clients through the complexities of regulatory frameworks, with her prowess extending to negotiating advantageous settlements.”

The IAM Patent 1000 identifies the top patent professionals and firms in key jurisdictions around the globe. The guide is compiled after an extensive research process. Individuals qualify for a listing in the IAM Patent 1000 when they receive sufficient positive feedback from peers and clients with knowledge of their practice and the market within which they operate. Firms qualify for a listing on the basis of their depth of knowledge, market presence, and the level of work on which they are typically engaged, as well as positive peer and client feedback.

About RMMS Headquartered in Chicago, RMMS is a full-service litigation and intellectual property law firm with over 30 attorneys devoted exclusively to the life sciences industry, including specialty practice in the field of patent and regulatory counseling and litigation under the Hatch-Waxman Act, the Medicare Prescription Drug, Improvement, and Modernization Act (MMA), and the Biologics Price Competition and Innovation Act (BPCIA).